<DOC>
	<DOCNO>NCT02444819</DOCNO>
	<brief_summary>A multi-center , single-arm . Phase 2 exploratory trial evaluate efficacy safety HM61713 1st-line anticancer agent none-small cell lung cancer patient EGFR mutation</brief_summary>
	<brief_title>Phase II Trial Evaluate Efficacy Safety HM61713 1st-line NSCLC Anticancer Therapy</brief_title>
	<detailed_description>HM-EMSI-201 study target NSCLC patient EGFR mutation HM61713 anticancer drug first-line therapy .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Aged least 19 year time signing informed consent Cytologically histologically confirm , advance metastatic NSCLC amenable curative surgery ( Stage IIIb IV ) Documented EGFR mutation ( exclude exon 20 insertion ) At least one lesion use measurable lesion per RECIST version 1.1 Performance status 1 per ECOG score Life expectancy least 12 week Adequate hematological biological function Provide voluntary consent participate study sign write consent form Treatment chemotherapy , biological therapy immunotherapy anticancer therapy stage IIIb IV NSCLC ( exclude adjuvant/neoadjuvant chemotherapy , radiotherapy radiochemotherapy prior 6 month first dose study treatment History treatment EGFR target small molecule antibody Any nonstudy related significant surgical procedure require general anesthesia breathing apparatus within past 4 week first dose study treatment ( exclude videoassisted thoracoscopic surgery openandclosed surgery prior past 2 week first dose study treatment ) History malignancy within 5 year study participation ( curatively treat cervical cancer situ , nonmelanoma skin cancer , superficial bladder tumor unless definitively treat evidence relapse recurrence within past 3 year ) Clinically significant uncontrolled condition infectious disease include active infection require parenteral antibiotic ( except condition definitively treat control ) Spinal cord compression , leptomeningeal carcinomatosis , symptomatic uncontrolled brain metastasis Presence history ILD pulmonary fibrosis NYHA class III IV cardiac insufficiency , uncontrolled hypertension , experience unstable angina pectoris cardiac infarction within 6 month , uncontrolled cardiac arrhythmia clinically significant abnormal cardiovascular activity LVEF &lt; 40 % Presence history pancreatitis serum amylase &gt; 1.5xULN Inability swallow formulate product gastrointestinal tract abnormality would preclude administration absorption study medication Mental congenital disability ( e.g . dementia epilepsy ) would preclude understand informed consent follow study protocol History hypersensitivity investigational drug relate similar class drug Pregnant breast feed Unwillingness adequate contraception study treatment least 2 month treatment Unwillingness follow procedure study protocol followup assessment ; Unable follow long term psychological , social , family problem geographical reason History treatment investigational drug investigational medical device prior 28 day first dose study treatment In opinion investigator , patient unsuitable candidate study ECG find QTcF &gt; 450 msec rest</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HM61713</keyword>
	<keyword>Epidermal Growth Factor Receptor mutation positive NSCLC</keyword>
	<keyword>olmutinib</keyword>
</DOC>